期刊文献+

盐酸伊立替康脂质体载药方式的研究进展 被引量:3

原文传递
导出
摘要 目的:介绍盐酸伊立替康(CPT-11)脂质体的载药方式,为其进一步研发提供参考。方法:根据文献,综述了硫酸铵梯度法、pH梯度法、二价阳离子载体A23187联合硫酸铜溶液法、金属离子梯度法和六磷酸肌醇作为载入剂等5种CPT-11脂质体的载药方式。结果与结论:利用上述载药方式所制备的CPT-11脂质体的包封率均大于90%。随着脂质体制备和研究技术的不断提高,开发长效、靶向的CPT-11脂质体,进而提高药物的治疗指数、优化药物的给药剂量和降低药物的毒副作用,已成为国内、外学者研究的热点。
出处 《中国药房》 CAS CSCD 北大核心 2011年第37期3536-3538,共3页 China Pharmacy
  • 相关文献

参考文献17

  • 1Weikersthal LF, Schalhorn A, Stauch M, et al. Phase trial of irinotecan plus infusional 5-fluorouracil/folinic ac- id versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer[J]. Eur J Cancer, 2011,47 (2):206.
  • 2Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (Irino- tecan) as a single agent in metastatic colorectal cancer[J]. Eur J Cancer, 1996,32 ( Suppl 3 ) : S 13.
  • 3Kakolyris S, Kouroussis CH, Souglakos J, et al. Cisplatin and irinotecan (CPT-11) as second-line treatment in pa- tients with advanced non-small cell lung cancer[J]. Lung Cancer, 2001,34(4) : 71.
  • 4Hofheinz R, Hartung G, Samel S, et al. Adding weekly iri- notecan to high-dose 5-fluorourouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase Ⅱ study[J]. Antican- cer Drugs, 2002,13(10) : 999.
  • 5Barenholz Y. Liposome application: problems and prospe- cts[J]. Curr Opin Colloidlnterface Sci, 2001,6( 1 ) : 66.
  • 6魏伟,邓英杰,张睿智,曹金娜,李文秀,高晓非.硫酸铵梯度法制备盐酸伊立替康脂质体及体外释放的研究[J].中国药剂学杂志(网络版),2009(1):20-30. 被引量:7
  • 7Chou TH, Chen SC, Chu IM. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method[J]. JBiosci Bioeng, 2003,95 (4) : 405.
  • 8Ramsay E, Alnajim J, Anantha M, et al. A novel liposo- mal irinotecan formulation with significant anti-tumour ac- tivity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention[J]. Eur JPharm Biopharm, 2008,68 (3) : 607.
  • 9Abraham SA, Edwards K, Karlsson G, et al. Formation of transition metal-doxorubicin complexes inside liposomes [J]. Biochim Biophys Acta, 2002,1 565 ( 1 ) :41.
  • 10Ramsay E, Alnajim J, Anantha M, et al. Transition metal- mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation[J]. Pharm Res, 2006,23(12) : 2 800.

二级参考文献12

  • 1Takeshi Matsuzaki,Teruo Yokokura,Masahiko Mutai,Takashi Tsuruo.Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice[J]. Cancer Chemotherapy and Pharmacology . 1988 (4)
  • 2Tsao YP,Russo A,Nyamuswa G,et al.Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV 40 DNA replication system. Cancer Research . 1993
  • 3Fassberg J,Stella V J.A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. Journal of Pharmacological Sciences . 1992
  • 4Burke TG,Mishra AK,Wani MC,et al.Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry . 1993
  • 5Haran G,Cohen R,Bar L K,et al.Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta . 1993
  • 6Szoka FC,Papahadjopoulos D.Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America . 1978
  • 7O’Reilly S,Rowinsky EK.The clinical status of irinotecon(CPT-11),anovel water soluble Camptothecin analogue:1996. Critical Reviews in Oncology Hematology . 1996
  • 8Torchilin V,Weissig V.Liposome: a practical approach. (Practical Approach Series) . 2003
  • 9Gregory Gregoriadis.Liposome Technology Volume I, Liposome Preparation and Related Techniques. . 1993
  • 10Senior,J. H.Fate and behavior of liposomes in vivo: a review of controlling factors. Critical Reviews in Therapeutic Drug Carrier Systems . 1987

共引文献6

同被引文献26

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部